Quarterly ResultJun 9, 2026, 06:07 AM
Burning Rock Q1 Revenue Down 18.9% to $15.6M; Net Loss $2.5M
AI Summary
Burning Rock Biotech Ltd reported a significant decline in its first quarter 2026 financial results. Total revenues decreased by 18.9% year-over-year to RMB107.9 million ($15.6 million), leading to a wider net loss of RMB17.5 million ($2.5 million) compared to the prior year. The revenue decline was observed across all business segments, primarily due to a decrease in test volumes and one-off issues affecting in-hospital revenue. The company also highlighted recent business updates, including presentations of multiple study results at the 2026 AACR and Journal for ImmunoTherapy of Cancer.
Key Highlights
- Total revenues were RMB107.9 million ($15.6 million), an 18.9% decrease year-over-year.
- Net loss was RMB17.5 million ($2.5 million), compared to RMB13.5 million loss in Q1 2025.
- Gross profit decreased by 19.9% to RMB78.0 million ($11.3 million).
- Central laboratory revenue was RMB32.3 million ($4.7 million), down 15.3% YoY.
- In-hospital business revenue was RMB52.8 million ($7.6 million), down 8.5% YoY.
- Pharma R&D services revenue was RMB22.8 million ($3.3 million), down 38.6% YoY.
- Operating expenses decreased by 14.0% to RMB96.9 million ($14.1 million).
- Cash, cash equivalents and restricted cash totaled RMB448.7 million ($65.1 million).
Price Impact
More from BNR